Getty Imagesand Australia at the Millennium Stadium on November 28, 2009 in Cardiff, Wales.
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Health & Biotech
share
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX.
Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in patients with focal segmental glomerulosclerosis (FSGS).
FSGS is a rare disease that attacks the kidney’s filtering units that could lead to permanent kidney damage and failure.
Dimerix’s Phase III study will assess the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB).
ImpediMed (ASX:IPD) rose by 25% this month after saying that its lead product SOZO has received a US FDA Breakthrough Device Designation for treatment and diagnosis of renal failure.
The company says the current process, which utilises weight scales to determine accumulation of fluid, has significant deficiencies.
SOZO is a bioimpedance spectroscopy (BIS) platform which tackles that problem by providing an exact measure of fluid volume to remove during a dialysis session.
Best and worst performing health stocks in August
| Code | Company | Price | %Mth | %Wk | MktCap |
|---|---|---|---|---|---|
| IDT | IDT Australia Ltd | 0.68 | 66 | 300 | $ 166,702,818.15 |
| IHL | Incannex Healthcare | 0.42 | 65 | 600 | $ 453,848,293.50 |
| RNO | Rhinomed Ltd | 0.345 | 64 | 316 | $ 93,909,378.84 |
| PXS | Pharmaxis Ltd | 0.135 | 42 | 41 | $ 56,696,379.88 |
| NEU | Neuren Pharmaceut. | 2.27 | 41 | 79 | $ 249,845,675.44 |
| DXB | Dimerix Ltd | 0.335 | 40 | -55 | $ 86,974,692.70 |
| EYE | Nova EYE Medical Ltd | 0.445 | 39 | 44 | $ 61,132,592.22 |
| RSH | Respiri Limited | 0.09 | 36 | -42 | $ 64,332,830.31 |
| IMU | Imugene Limited | 0.395 | 34 | 618 | $ 2,212,370,606.24 |
| IPD | Impedimed Limited | 0.125 | 32 | 81 | $ 186,768,937.38 |
| TLX | Telix Pharmaceutical | 7.05 | 25 | 327 | $ 1,912,222,940.32 |
| BNO | Bionomics Limited | 0.185 | 23 | 52 | $ 186,405,397.64 |
| CPH | Creso Pharma Ltd | 0.135 | 23 | 286 | $ 155,553,317.66 |
| IMM | Immutep Ltd | 0.575 | 20 | 195 | $ 450,989,084.53 |
| LBT | LBT Innovations | 0.125 | 19 | 0 | $ 37,584,971.32 |
| ILA | Island Pharma | 0.345 | 19 | $ 14,815,392.27 | |
| GSS | Genetic Signatures | 1.48 | 18 | -35 | $ 211,502,724.08 |
| BXN | Bioxyne Ltd | 0.033 | 18 | 136 | $ 21,124,798.13 |
| SDI | SDI Limited | 1.04 | 18 | 49 | $ 124,214,478.85 |
| AMT | Allegra Orthopaedics | 0.235 | 18 | 24 | $ 24,547,912.71 |
| HXL | Hexima | 0.27 | 17 | -11 | $ 34,907,998.61 |
| MXC | Mgc Pharmaceuticals | 0.048 | 17 | 92 | $ 112,068,050.35 |
| KZA | Kazia Therapeutics | 1.43 | 16 | 36 | $ 182,922,048.42 |
| MVF | Monash IVF Group Ltd | 0.9975 | 15 | 57 | $ 389,634,840.00 |
| ONT | 1300 Smiles Limited | 8 | 14 | 28 | $ 189,900,639.68 |
| VLS | Vita Life Sciences.. | 1.235 | 14 | 40 | $ 64,631,081.23 |
| OVN | Oventus Medical Ltd | 0.11 | 13 | -58 | $ 24,172,653.50 |
| RAP | Resapp Health Ltd | 0.045 | 13 | -63 | $ 38,663,868.47 |
| PGC | Paragon Care Limited | 0.29 | 12 | 41 | $ 101,365,587.60 |
| CYP | Cynata Therapeutics | 0.515 | 10 | -42 | $ 74,503,828.88 |
| BOT | Botanix Pharma Ltd | 0.082 | 8 | 71 | $ 77,851,365.92 |
| OIL | Optiscan Imaging | 0.22 | 7 | 249 | $ 138,804,885.45 |
| 1AD | Adalta Limited | 0.091 | 7 | -13 | $ 22,311,341.60 |
| OPT | Opthea Limited | 1.33 | 6 | -49 | $ 459,814,638.71 |
| UBI | Universal Biosensors | 0.84 | 6 | 171 | $ 154,619,458.92 |
| VBS | Vectus Biosystems | 1.32 | 6 | 17 | $ 41,785,120.08 |
| LDX | Lumos Diagnostics | 1.19 | 5 | $ 187,690,516.25 | |
| PTX | Prescient Ltd | 0.205 | 5 | 181 | $ 125,303,015.76 |
| CMP | Compumedics Limited | 0.41 | 5 | 5 | $ 72,636,808.68 |
| VHT | Volpara Health Tech | 1.175 | 5 | -15 | $ 294,083,104.77 |
| CBL | Control Bionics | 0.68 | 5 | $ 36,238,252.32 | |
| 4DX | 4Dmedical Limited | 1.61 | 5 | 8 | $ 333,284,441.99 |
| OSL | Oncosil Medical | 0.048 | 4 | -58 | $ 38,272,478.11 |
| CAJ | Capitol Health | 0.37 | 4 | 42 | $ 386,905,317.00 |
| SUD | Suda Pharmaceuticals | 0.051 | 4 | 4 | $ 24,040,999.30 |
| CTE | Cryosite Limited | 0.45 | 3 | 165 | $ 21,086,803.35 |
| PBP | Probiotec Limited | 2.2 | 3 | 19 | $ 171,834,859.14 |
| NC6 | Nanollose Limited | 0.098 | 3 | 51 | $ 13,976,518.59 |
| RHY | Rhythm Biosciences | 0.9375 | 3 | 755 | $ 187,077,375.18 |
| CAN | Cann Group Ltd | 0.2925 | 3 | -27 | $ 93,177,485.10 |
| MMJ | MMJ Group Hlds Ltd | 0.081 | 3 | -13 | $ 18,626,272.79 |
| ACW | Actinogen Medical | 0.1075 | 2 | 322 | $ 182,661,440.17 |
| NTI | Neurotech Intl | 0.045 | 2 | 200 | $ 34,144,137.17 |
| BD1 | Bard1 Life Sciences | 1.41 | 2 | 62 | $ 129,168,562.60 |
| GLH | Global Health Ltd | 0.5 | 2 | 117 | $ 28,283,862.50 |
| TRU | Truscreen | 0.06 | 2 | $ 20,320,510.17 | |
| MEM | Memphasys Ltd | 0.065 | 2 | -43 | $ 44,885,658.92 |
| OSX | Osteopore Limited | 0.375 | 1 | -36 | $ 28,093,608.00 |
| IBX | Imagion Biosys Ltd | 0.0705 | 1 | -23 | $ 73,030,176.24 |
| CYC | Cyclopharm Limited | 1.665 | 0 | 21 | $ 155,469,080.30 |
| ACR | Acrux Limited | 0.125 | 0 | -31 | $ 35,413,174.25 |
| ALC | Alcidion Group Ltd | 0.38 | 0 | 171 | $ 382,545,203.98 |
| RGS | Regeneus Ltd | 0.076 | 0 | -54 | $ 23,068,915.59 |
| IMC | Immuron Limited | 0.16 | 0 | -52 | $ 36,359,455.36 |
| ICS | ICSGlobal Limited | 0.575313 | 0 | 13 | $ 6,054,604.94 |
| EXL | Elixinol Wellness | 0.115 | 0 | -30 | $ 34,656,946.94 |
| AVE | Avecho Biotech Ltd | 0.017 | 0 | 113 | $ 29,377,864.42 |
| ALT | Analytica Limited | 0.002 | 0 | -33 | $ 9,227,602.26 |
| AHK | Ark Mines Limited | 0.034 | 0 | 0 | $ 1,778,919.95 |
| JHC | Japara Healthcare Lt | 1.3725 | -1 | 202 | $ 366,128,839.36 |
| CGS | Cogstate Ltd | 1.66 | -1 | 129 | $ 289,825,221.05 |
| FFC | Farmaforce Ltd | 0.066 | -1 | 27 | $ 8,624,944.68 |
| BWX | BWX Limited | 4.91 | -2 | -3 | $ 720,666,842.40 |
| M7T | Mach7 Tech Limited | 0.96 | -2 | -15 | $ 219,942,875.88 |
| NSB | Neuroscientific | 0.325 | -3 | 41 | $ 48,780,358.62 |
| CHM | Chimeric Therapeutic | 0.32 | -3 | $ 62,816,382.41 | |
| AT1 | Atomo Diagnostics | 0.2275 | -3 | -46 | $ 93,998,777.51 |
| NYR | Nyrada Inc. | 0.29 | -3 | 38 | $ 34,412,797.16 |
| PSQ | Pacific Smiles Grp | 2.4 | -4 | 30 | $ 381,400,831.82 |
| PNV | Polynovo Limited | 2.155 | -4 | -2 | $ 1,474,895,338.12 |
| MVP | Medical Developments | 3.61 | -4 | -39 | $ 259,403,406.08 |
| CDX | Cardiex Limited | 0.067 | -4 | 24 | $ 60,192,480.08 |
| MX1 | Micro-X Limited | 0.285 | -5 | 50 | $ 126,417,978.50 |
| CDY | Cellmid Limited | 0.052 | -5 | -49 | $ 9,746,389.12 |
| BDX | Bcaldiagnostics | 0.17 | -6 | $ 21,044,249.92 | |
| SOM | SomnoMed Limited | 2.2 | -6 | 38 | $ 182,898,086.15 |
| ATH | Alterity Therap Ltd | 0.032 | -6 | -40 | $ 79,426,861.07 |
| PYC | PYC Therapeutics | 0.15 | -6 | 26 | $ 477,138,915.45 |
| ADR | Adherium Ltd | 0.015 | -6 | -61 | $ 31,936,289.40 |
| EZZ | EZZ Life Science | 0.41 | -6 | $ 5,040,000.00 | |
| HCT | Holista CollTech Ltd | 0.058 | -6 | -2 | $ 15,970,247.05 |
| AHC | Austco Healthcare | 0.145 | -6 | 81 | $ 41,207,397.90 |
| MEB | Medibio Limited | 0.007 | -7 | -42 | $ 13,462,961.24 |
| EPN | Epsilon Healthcare | 0.14 | -7 | -40 | $ 26,978,972.86 |
| MDR | Medadvisor Limited | 0.325 | -7 | -28 | $ 122,649,480.85 |
| ATX | Amplia Therapeutics | 0.19 | -7 | 36 | $ 24,340,161.30 |
| ICR | Intelicare Holdings | 0.125 | -7 | -63 | $ 5,399,322.57 |
| PAA | Pharmaust Limited | 0.085 | -8 | -54 | $ 26,937,552.56 |
| LCT | Living Cell Tech. | 0.012 | -8 | -40 | $ 6,857,291.77 |
| MDC | Medlab Clinical Ltd | 0.175 | -8 | 13 | $ 59,880,742.43 |
| RAC | Race Oncology Ltd | 3.08 | -8 | 285 | $ 448,427,032.92 |
| VTI | Vision Tech, Inc | 1.02 | -8 | -59 | $ 24,699,097.50 |
| ARX | Aroa Biosurgery | 1.05 | -8 | -20 | $ 358,955,956.80 |
| AC8 | Auscann Grp Hlgs Ltd | 0.096 | -9 | -34 | $ 41,411,428.34 |
| NXS | Next Science Limited | 1.455 | -9 | 10 | $ 291,021,646.23 |
| DOC | Doctor Care Anywhere | 0.735 | -9 | $ 132,762,459.46 | |
| ANP | Antisense Therapeut. | 0.19 | -10 | 111 | $ 109,150,505.17 |
| BPH | BPH Energy Ltd | 0.064 | -10 | 94 | $ 43,219,760.29 |
| PAR | Paradigm Bio. | 1.9875 | -10 | -30 | $ 449,913,675.42 |
| ONE | Oneview Healthcare | 0.38 | -11 | 850 | $ 164,640,796.14 |
| PIQ | Proteomics Int Lab | 1.07 | -11 | 75 | $ 115,781,462.50 |
| SCU | Stemcell United Ltd | 0.016 | -11 | 23 | $ 16,693,130.53 |
| BIT | Biotron Limited | 0.052 | -12 | -44 | $ 37,202,433.79 |
| S66 | Star Combo | 0.33 | -12 | -8 | $ 45,802,239.46 |
| GTG | Genetic Technologies | 0.007 | -13 | -30 | $ 69,195,676.07 |
| IVX | Invion Ltd | 0.013 | -13 | 18 | $ 72,014,049.84 |
| NOX | Noxopharm Limited | 0.515 | -13 | 69 | $ 157,110,689.78 |
| 1ST | 1St Group Ltd | 0.019 | -14 | -47 | $ 8,067,721.16 |
| APH | AP Hemp Ltd | 0.315 | -14 | 125 | $ 23,687,141.85 |
| TD1 | Tali Digital Limited | 0.0345 | -14 | 44 | $ 31,684,796.83 |
| DVL | Dorsavi Ltd | 0.023 | -15 | 9 | $ 8,082,949.16 |
| OCC | Orthocell Limited | 0.45 | -16 | 1 | $ 87,898,234.28 |
| ZLD | Zelira Therapeutics | 0.037 | -16 | -39 | $ 44,041,949.74 |
| PAB | Patrys Limited | 0.042 | -16 | 252 | $ 72,783,876.20 |
| LSH | Lifespot Health Ltd | 0.084 | -16 | 140 | $ 14,151,224.39 |
| PCK | Painchek Ltd | 0.047 | -16 | -51 | $ 54,326,630.35 |
| AGH | Althea Group | 0.255 | -20 | -33 | $ 61,657,781.90 |
| RCE | Recce Pharmaceutical | 0.75 | -21 | -49 | $ 131,202,274.49 |
| JTL | Jayex Technology Ltd | 0.021 | -25 | -30 | $ 5,070,436.92 |
| SHG | Singular Health | 0.215 | -26 | $ 13,909,098.63 | |
| ADO | Anteotech Ltd | 0.165 | -27 | 206 | $ 315,262,674.56 |
| PAL | Palla Pharma Ltd | 0.27 | -27 | -65 | $ 61,527,001.94 |
| ZNO | Zoono Group Ltd | 0.48 | -28 | -79 | $ 84,207,480.57 |
| RHT | Resonance Health | 0.115 | -30 | -18 | $ 52,997,977.82 |
| OSP | Osprey Med Inc | 0.011 | -31 | -61 | $ 28,223,583.06 |
| CU6 | Clarity Pharma | 1.42 | $ 236,595,760.83 |
IDT Australia (ASX:IDT) was the best healthcare stock on the ASX in August, rising by more than 60%.
Last week, the company announced that it has formalised activities with the Australian Government to potentially assist with the production of a COVID-19 vaccine.
IDT says it signed a Sterile Readiness Agreement with the government to bring its sterile manufacturing facility into a state of readiness to potentially produce the vaccine.
Cannabis play Incannex Healthcare (ASX:IHL) soared by 65% this month, following an announcement that it has lodged a registration form with US SEC for a potential dual listing on the Nadsaq.
In comments to Stockhead, Incannex highlighted the strategic rationale for the US listing, which it said would provide greater access to a larger pool of global investors.
Pharmaxis (ASX:PXS) rose by 35% this month after announcing its treatment to prevent wound and burn scars has cleared the Phase 1 trial, and will now advance to the next stage of development in patients.
In a study of healthy volunteers led by renowned surgeon Professor Fiona Wood AM, the Pharmaxis drug PXS‐6302 demonstrated good tolerability and full inhibition of the enzymes being targeted to prevent scarring.
Earlier in the month, the company granted Aptar Pharma the option to acquire the worldwide rights to Pharmaxis’ proprietary inhaler, Orbital, a unique device designed to deliver high payload dry powder to the lungs.
Best earnings picks
August was earnings season and there were some interesting results to pick from in the Health sector.
Virtus Health (ASX:VRT) delivered a full year FY21 revenue of $324.6m, compared to FY20 revenue of $258.9m.
The company also entered into a binding agreement with Healius (ASX:HLS) to buy Healius’ Adora Fertility business and three co-located Healius Day Hospitals for $45m.
Monash IVF Group (ASX:MVF) posted strong FY21 results, with full year NPAT up by 61.5% to $23.3m.
Promedicus (ASX:PME) also recorded another year of strong growth across all metrics. The company reported a 19.5% jump in revenue to $67.9m and a 43% increase in EBIT to $42.7m.
Dental facilities 1300 Smiles (ASX:ONT) meanwhile, has received a takeover offer from Abano Healthcare for $8.00 per share less dividends.
In an interesting turn of events, the offer comes less than two years after ONT’s attempt to secure Abano’s Australian portfolio of 116 practices.
Read MoreBiotech
